Routine noninvasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women-2years of screening experience from Denmark

Prenatal Diagnosis

Volumn 34, Issue 10, 2014, Pages 1000-1005

  Clausen, F Banch ^a   Steffensen, R ^b   Christiansen, M ^c   Rudby, M ^d   Jakobsen, M A ^e   Jakobsen, T R ^a   Krog, G R ^a   Madsen, R D ^c   Nielsen, K R ^b   Rieneck, K ^a   Sprogoe U ^e   Homburg, K M ^d   Baech, J ^b   Dziegiel, M H ^a   Grunnet, N ^c  

^a Mental Health Services CPH   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d NAESTVED HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS D ANTIBODY; BLOOD GROUP RHESUS SYSTEM; FETOPROTEIN; RHO(D) ANTIGEN;

ARTICLE; BLOOD ANALYSIS; BLOOD GROUP RHESUS SYSTEM; BLOOD SAMPLING; CONTROLLED STUDY; DENMARK; DIAGNOSTIC TEST ACCURACY STUDY; EXON; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FETUS; GENETIC SCREENING; GENOTYPE; GESTATIONAL AGE; HETEROZYGOTE; HUMAN; IMMUNOPROPHYLAXIS; MAJOR CLINICAL STUDY; MASS SCREENING; MATERNAL BLOOD; NEWBORN; NON INVASIVE MEASUREMENT; PREGNANT WOMAN; PRENATAL SCREENING; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; REAL TIME POLYMERASE CHAIN REACTION; RHD GENE; RHESUS INCOMPATIBILITY; SENSITIVITY AND SPECIFICITY; UMBILICAL CORD BLOOD; BLOOD; MATERNAL SERUM SCREENING TEST; PREGNANCY; STATISTICS AND NUMERICAL DATA;

DENMARK; FEMALE; FETAL PROTEINS; HUMANS; INFANT, NEWBORN; MATERNAL SERUM SCREENING TESTS; PREGNANCY; RH-HR BLOOD-GROUP SYSTEM;

EID: 84908232413     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4419     Document Type: Article

References (39)

1. Lo YMD, Chiu RWK. Genomic analysis of fetal nucleic acids in maternal blood. Annu Rev Genomics Hum Genet 2012;13:285-306.
2. Bianchi DW. From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges. Nat Med 2012;18:1041-51.
3. Hill M, Barrett AN, White H, Chitty LS. Uses of cell free fetal DNA in maternal circulation. Best Pract Res Clin Obstet Gynaecol 2012;26:639-54.
4. Simpson JL. Cell-free fetal DNA and maternal serum analytes for monitoring embryonic and fetal status. Fertil Steril 2013;99:1124-34.
5. Hui L, Bianchi DW. Recent advances in the prenatal interrogation of the human fetal genome. Trends Genet 2013;29:84-91.
6. Scheffer PG, van der Schoot CE, Page-Christians GCML, de Haas M. Noninvasive fetal blood group genotyping of rhesus D, c, E and K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG 2011;118:1340-8.
7. Daniels G, Finning K, Martin P, Massey E. Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat Diagn 2009;29:101-7.
8. Lo YMD, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7.
9. Faas BHW, Beuling EA, Christiaens GCML, et al. Detection of fetal RHD-specific sequences in maternal plasma. Lancet 1998;352:1196.
10. Lo YMD, Hjelm NM, Fidler C, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998;339:1734-8.
11. Lo YMD, Tein MSC, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998;62:768-75.
12. van der Schoot E, Hahn S, Chitty LS. Non-invasive prenatal diagnosis and determination of fetal Rh status. Semin Fetal Neonatal Med 2008;13:63-8.
13. Geifman-Holtzman O, Grotegut CA, Gaughan JP. Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood-a meta-analysis. Am J Obstet Gynecol 2006;195:1163-73.
14. Legler TJ, Müller SP, Haverkamp A, et al. Prenatal RhD testing: a review of studies published from 2006 to 2008. Transfus Med Hemother 2009;36:189-98.
15. Scheffer PG, de Haas M, van der Schoot CE. The controversy about controls for fetal blood group genotyping by cell-free fetal DNA in maternal plasma. Curr Opin Hematol 2011;18:467-73.
16. Clausen FB. Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care. Prenat Diagn 2014;34:1-7. DOI: 10.1002/pd.4326
17. Hill M, Finning K, Martin P, et al. Non-invasive prenatal determination of fetal sex: translating research into clinical practice. Clin Genet 2011;80:68-75.
18. Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev 2000;14:44-61.
19. Hirose TG, Mays DA. The safety of RhIG in the prevention of haemolytic disease of the newborn. J Obstet Gynaecol 2007;27:545-57.
20. de Haas M, Finning K, Massey E, Roberts DJ. Anti-D prophylaxis: past, present and future. Transfus Med 2014;24:1-7.
21. Urbaniak SJ. The scientific basis of antenatal prophylaxis. BJOG 1998;105(Supplement 18):11-8.
22. Crowther C. Anti-D administration in pregnancy for preventing Rhesus allo-immunization (Cochrane review) I. The Cochrane Library 2004, issue 2.
23. Koelewijn JM, de Haas M, Vrijkotte TG, et al. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion 2008;48:1721-9.
24. Tiblad E, Taune Wikman A, Ajne G, et al. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation-outcome of a new antenatal screening and prevention program. PLoS One 2013;8:e70984:1-7.
25. van der Schoot CE, Soussan AA, Koelewijn J, et al. Non-invasive antenatal RHD typing. Transfus Clin Biol 2006;13:53-7.
26. Finning K, Martin P, Summers J, et al. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 2008;336:816-8.
27. Müller SP, Bartels I, Stein W, et al. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion 2008;48:2292-301.
28. Clausen FB, Christiansen M, Steffensen R, et al. Report of the first nationally implemented clinical routine screening for fetal RHD in RhD negative women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2012;52:752-8.
29. de Haas M, van der Ploeg CPB, Scheffer PG, et al. A nation-wide fetal RHD screening programme for targeted antenatal and postnatal anti-D. ISBT Sci Series 2012;7:164-7.
30. Wikman AT, Tiblad E, Karlsson A, et al. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012;120:227-34.
31. Fagredaktion S, Brot C, Poulsen A. Anbefalinger for Svangreomsorgen [Recommendations for Pregnancy and Birth] (1st edn). Danish National Board of Health: Copenhagen, 1st print ISBN: 978-87-7676-906-2. 2009.
32. Daniels G, Finnning K, Wade A, et al. Implementation of routine of fetal RHD typing in all RHD-negative pregnant women: timing, costs, and efficiency. Vox Sang 2012;103(suppl. 1):34.
33. Metcalfe P, Rigsby P, Tait E, Urbaniak S. An international reference reagent for the detection of RHD and SRY DNA in plasma. Vox Sang 2012;102:243-9.
34. Müller SP, Bartels I, Stein W, et al. Cell-free fetal DNA in specimen from pregnant women is stable up to 5days. Prenat Diagn 2011;31:1300-4.
35. Clausen FB, Jakobsen TR, Rieneck K, et al. Pre-analytical conditions in non-invasive prenatal testing of cell-free fetal RHD. PLoS One 2013;8:e76990:1-8.
36. Damkjær MB, Perslev A, Clausen FB, et al. Study of compliance with a new, targeted antenatal D immunization prevention program in Denmark. Vox Sang 2012;103:145-9.
37. Koby L, Grunbaum A, Benjamin A, et al. Anti-D in Rh(D)-negative pregnant women: are at-risk pregnancies and deliveries receiving appropriate prophylaxis? J Obstet Gynaecol Can 2012;34:429-35.
38. Larsen JF, Bock JE, Jørgensen JR. Forebyggelse af Rhesusimmunisering. Ugeskr Lægre 2004;166:3073-8.
39. de Haas M, van der Schoot E. Prenatal screening. ISBT Sci Series 2013;8:6-10.